The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
48
NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin.
Placebo matched to NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin.
PAREXEL Glendale/LA EPCU
Glendale, California, United States
RECRUITINGPAREXEL Intl - EPCU-Baltimore
Baltimore, Maryland, United States
RECRUITINGNumber of treatment emergent adverse events (TEAEs)
Measured as number of events.
Time frame: From time of dosing (day 1) up to day 43
AUC: Area under the NNC0113-5840 plasma concentration time-curve
Measured as hours\*nanomole per liter (h\*nmol/L)
Time frame: From pre-dose (day 1) up to day 43
Cmax: Maximum observed NNC0113-5840 plasma concentration
Measured as nanomoles per liter (nmol/L)
Time frame: From pre-dose (day 1) up to day 43
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.